Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors.

Macromolecule Content

• Total Structure Weight: 29.79 kDa 
• Atom Count: 1953 
• Residue Count: 254 
• Unique protein chains: 1

5U65

Camel Nanobody VHH-5

• DOI: 10.2210/pdb5U65/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Camelus dromedarius
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2016-12-07 Released: 2017-09-20 
• Deposition Author(s): Stanfield, R.L., Wilson, I.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 0.261 
• R-Value Work: 0.201 
• R-Value Observed: 0.204 

Literature

Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers.

Koch, K., Kalusche, S., Torres, J.L., Stanfield, R.L., Danquah, W., Khazanehdari, K., von Briesen, H., Geertsma, E.R., Wilson, I.A., Wernery, U., Koch-Nolte, F., Ward, A.B., Dietrich, U.

(2017) Sci Rep 7: 8390-8390

• PubMed: 28827559 
• DOI: 10.1038/s41598-017-08273-7
• Structures With Same Primary Citation


• PubMed Abstract: 
  

Broadly neutralizing antibodies (bnAbs) against HIV-1 protect from infection and reduce viral load upon therapeutic applications. However no vaccine was able so far to induce bnAbs demanding their expensive biotechnological production. For clinical applications, nanobodies (VHH) derived from heavy chain only antibodies from Camelidae, may be better suited due to their small size, high solubility/stability and extensive homology to human VH3 genes. Here we selected broadly neutralizing nanobodies by phage display after immunization of dromedaries with different soluble trimeric envelope proteins derived from HIV-1 subtype C. We identified 25 distinct VHH families binding trimeric Env, of which 6 neutralized heterologous primary isolates of various HIV-1 subtypes in a standardized in vitro neutralization assay. The complementary neutralization pattern of two selected VHHs in combination covers 19 out of 21 HIV-1 strains from a standardized panel of epidemiologically relevant HIV-1 subtypes. The CD4 binding site was preferentially targeted by the broadly neutralizing VHHs as determined by competition ELISAs and 3D models of VHH-Env complexes derived from negative stain electron microscopy. The nanobodies identified here are excellent candidates for further preclinical/clinical development for prophylactic and therapeutic applications due to their potency and their complementary neutralization patterns covering the majority of epidemiologically relevant HIV-1 subtypes.

---

Organizational Affiliation: 

Georg-Speyer-Haus, Paul-Ehrlich-Str, 42-44, 60596, Frankfurt, Germany. [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
VHH-5	A, B	138	Camelus dromedarius	Mutation(s): 0

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
SO4	A	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.30 Å
• R-Value Free: 0.261 
• R-Value Work: 0.201 
• R-Value Observed: 0.204 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 89.41	α = 90
b = 48.48	β = 114.67
c = 60.89	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
XDS	data reduction
XSCALE	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2016-12-07 
• Released Date: 2017-09-20 
Deposition Author(s): Stanfield, R.L., Wilson, I.A.

Revision History 

• Version 1.0: 2017-09-20
  Type: Initial release